BioSpace News Archive

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2024.

Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced financial results for the first quarter ended March 31, 2024.

NeuroPace, Inc., a medical device company focused on transforming the lives of people living with epilepsy, announced it will participate in two healthcare conferences in May.

ProMIS Neurosciences Inc. announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.

AEON Biopharma, Inc. announced financial results for the first quarter ended March 31, 2024, and provided a business update.

KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Bolt Biotherapeutics reported financial results for the first quarter ended March 31, 2024 and announced a strategic prioritization as well as changes to its leadership team.

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced its financial results for the first quarter of 2024 and highlighted recent Company progress.

Akili, Inc., a leading digital medicine company, reported its financial results for the quarter ended March 31, 2024 and provided an update on business progress.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2024.